Authors
Latest:
Discussing Patient Characteristics in ESCC On Ipilimumab/NivolumabKen Kato, MD, PhD, discusses which patient characteristics to look out for when looking to put a patient on the combination of ipilimumab and nivolumab.
Latest:
Improved Safety Measures Mark Newest Treatments in Soft Tissue SarcomaIn early 2020, the treatment paradigm of soft tissue sarcoma had 3 notable advancements with the FDA approving therapies in epithelioid sarcoma, Kaposi sarcoma, and gastrointestinal stromal tumors.
Latest:
Looking Towards the Future of Molecular Testing and Additional Treatment Options for Patients with mNSCLCThe panel closes by summarizing recent advances in the field and shares hopes for future improvements in molecular testing and treatment options for patients with mNSCLC.
Latest:
Overall Survival Improved With 177 Lu-Dotatate for Patients With Progressive Midgut NETsFinal overall survival and long-term safety results of the phase 3 NETTER-1 trial were presented during the World Congress on Gastrointestinal Cancer 2021.
Latest:
Challenges Hinder Machine Learning's Potential in OncologyJames Zou, PhD, elaborates on some of the challenges associated with machine learning techniques and its utilization in oncology.
Latest:
Management of HR+, HER2- Early-Stage Breast Cancer After DiagnosisPhysicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.
Latest:
Real-World Outcomes of Brexu-cel in R/R B-Cell ALLEvandro D. Bezerra, MD, provides real-world data from the CIBMTR Registry, examining the effectiveness of brexucabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Latest:
Detecting and Addressing Hard-to-Find Skin CancersNiraj H. Mehta, MD, reviews the areas of the body where skin cancer can be hard to detect, what the skin cancer will look like on those parts of the body, risk factors for those receiving treatment, and follow-up for patients to catch recurrences.
Latest:
Expanding Allogeneic Stem Cell Transplantation for Relapsed and Refractory Acute Myeloid LeukemiaAllogeneic HCT has shown promise as definitive treatment for patients with relapsed or refractory AML.
Latest:
Future Research Aims to Examine Blocking STAT3 in Acute Myeloid LeukemiaMarcin Kortylewski, PhD, discusses what research he believes is next to come in the acute myeloid leukemia space.
Latest:
Individulizing Treatment and Exploring Options in Ovarian CancerChristina Fotopoulou, MD, PhD, discusses recent developments in ovarian cancer and explains how one can individualize treatments when managing patients.
Latest:
How Data Help Physicians Improve Operations and Achieve Health EquityA US health care executive survey found 30% see health equity solely as a social concern. Yet, it's about ensuring everyone has a fair shot at optimal health. Utilizing standardized data can shift care from reactive to preventive, easing strain on systems.
Latest:
Glioblastoma Treatment Is Slow to Change, but New Strategies Are Under InvestigationDuring the past 4 decades, glioblastoma has remained a cancer with one of the worst prognoses and is among the most debilitating.
Latest:
Steady Progress of AI Makes its Mark in the ClinicIncreasingly, and with exponential pace, AI algorithms are finding their way into the oncology clinic.
Latest:
EP. 2B: Challenges Affecting the Management of Extensive-Stage Small Cell Lung CancerIn this companion article, Dr. Jared Weiss provides key insights into recent advancements in the standard of care for extensive-stage small cell lung cancer and examines challenges affecting treatment.
Latest:
Key Takeaways from SABCS 2023 in HER2+ Breast CancerFollowing their review of clinical trial data presented at SABCS 2023, the Oncology Brothers discuss their key takeaways on recent updates in HER2+ breast cancer.
Latest:
Next Steps to Further Understand Uterine SarcomaMatthew A. Ingham, MD, discusses the key takeaways from an article he co-authored regarding novel therapeutics in uterine sarcoma.
Latest:
Imetelstat and Canakinumab in Lower-Risk MDSDrs Safah and Koprivinikar discuss emerging therapies, such as imetelstat and canakinumab, and where they might fit in the treatment paradigm for lower-risk MDS.
Latest:
Trial Results Show Patients With RET Alterations Experience Different Efficacy With Lung Cancer TherapiesDuring a Targeted Oncology Case-Based Peer Perspectives event, Todd Bauer, MD, medical oncologist, Tennessee Oncology, discussed the results from clinical trials that include patients with RET-altered lung cancer to determine a treatment strategy for a 59-year-old patient.
Latest:
Keeping Track of FGFR Inhibitor AEs Leads to Optimal OutcomesThis article explorex some of the more frequently encountered toxicities of FGFR inhibitors and their optimal management.
Latest:
Phase 2 Trial of Selinexor Shows Durable Responses in DLBCLMichael Schuster, MD, discusses the efficacy of treatment with selinexor in patients with diffuse large B-cell lymphoma in the SADAL study.
Latest:
Caring for Patients With Cancer as COVID Rates Continue to RiseStringent and dedicated interventions are necessary to handle the spread of COVID-19, as this represents a major healthcare challenge for humanity, says Daniel Vorobiof, MD.
Latest:
Discussing Treatment Options and Recent Trials in the Thyroid Cancer SpaceMelanie Goldfarb, MD, MSc, FACS, FACE, discusses the current treatment landscape for patients with thyroid cancer.
Latest:
Unmet Needs and Future Directions for Ovarian CancerThomas C. Krivak MD, John K. Chan, MD, and Cecelia H. Boardman, MD, share insight on recent updates to maintenance therapy, unmet needs, and the future treatment landscape for ovarian cancer.
Latest:
Pembrolizumab Improves PFS in Hodgkin Lymphoma Compared With Brentuximab VedotinJohn Kuruvilla, MD, FRCPC, discussed the positive findings for pembrolizumab compared with brentuximab vedotin in patients with Hodgkin lymphoma in the KEYNOTE-204 study.
Latest:
Rationale for Adding BDC-1001 to Immune Checkpoint Inhibitor Therapy in HER2+ Breast CancerEcaterina Ileana Dumbrava, MD, discusses the rationale for combing BDC-1001, a HER2-targeting TLR7/8 immune-stimulating antibody conjugate with an immune checkpoint inhibitor.
Latest:
SCLC: Treatment Advancing 1 Small, but Quickening, Step at a TimeIn 2019, there were approximately 30,000 new cases of small cell lung cancer diagnosed in the United States with nearly all cases attributable to cigarette smoking.
Latest:
Cervical Cancer Awareness Month: Dramatic Increase in Cervical Cancer Research Is Driving Treatment ProgressFor cervical cancer awareness month, Lauren Bollinger, MD, discusses how the increase in research in the field of cervical cancer is driving the progress of treatment.
